reSee.it - Related Video Feed

Artificial intelligence is returning to medicine not as a curiosity but as a driver of drug discovery and development. The typical pipeline begins with a biological insight and a therapeutic hypothesis about how modulating a target could help a patient, then moves to creating the right chemical matter, and finally to clinical development in people. The farther you go, the more expensive it gets, with clinical development being the costliest and most failure-prone stage. Depending on the estimate you trust, only about 5 to 10 percent of molecules entering the final clinical phase emerge with regulatory approval. The industry’s cost mood has spiraled, with fully loaded programs now soaring north of 2.6 billion dollars. Advances in AI are accelerating the middle piece of this journey: turning a target into a drug by designing effective molecules and screening vast libraries. The protein space benefits especially because advances like AlphaFold give structural context that makes it easier to predict how a molecule will interact with a protein. In addition, the explosion of multi-modal biological data—from cells and tissues to single-cell profiling and imaging—creates raw material for AI to interrogate biology at scale. Yet there is a gap: AI can rapidly generate hypotheses and designs, but turning new biological insights into disease-modifying therapies remains the harder, slower part of the journey. The strongest potential lies in redefining disease biology itself and identifying precise subtypes that respond to specific interventions. Data and incentives shape what is possible. A transformation in health care data collection and sharing is needed: richer, harmonized data from patients, with appropriate anonymization and safeguards. The talk notes that incentives in the United States often do not align with comprehensive diagnostics and data-driven treatment choices, and that centralized health data repositories could unlock breakthroughs much faster. Collaboration between academia and industry is essential, balancing deep theoretical thinking with product-like execution. The optimism rests on an exponential trajectory across AI, biology, and medicines, with the pace of change accelerating as measurement improves and integration tightens, ultimately enabling more precise, effective therapies.

AI and government data governance collide in a fast-moving conversation about how we communicate, secure, and protect records in a digital age. The discussion probes whether government use of Signal is safer than traditional tools, noting Signal's end-to-end encryption, its focus on individual privacy, and the risk of user errors that expose sensitive plans. It points to operational security failures and argues that, with competent use and up-to-date tech, Signal can remain a strong option for official dialogue, even as questions about data retention and access linger. Another thread moves to medicine, where an NHS hospital used AI to perform instant skin cancer checks, cutting clinical time by about 75 percent while preserving diagnostic accuracy. The talk shifts to regulatory and ethical hurdles of medical AI, including data ownership, contracts with big tech, and balancing speed with safeguards. It envisions a future where phones and wearables host diagnostic AI, expanding reach, while regulators and health systems race to define rules that enable rapid progress without compromising privacy.

The episode discusses significant developments in technology, particularly focusing on Bitcoin, AI, and the growing influence of Saudi Arabia in these sectors. Experts predict a bull run for Bitcoin, with notable figures like Mike Sailor doubling down on investments. The conversation highlights the increasing legitimacy of Bitcoin, with major corporations considering it for treasury reserves, and the potential for Bitcoin to reach unprecedented values if a small percentage of global wealth is allocated to it. The hosts also explore the rapid advancements in AI, particularly in Saudi Arabia, where partnerships between companies like Amazon and local AI firms are forming. The sale of Nvidia chips to Saudi Arabia signifies a major investment in AI infrastructure, aiming to create culturally relevant AI models. The discussion emphasizes the urgency for nations to innovate quickly in AI, as the competition intensifies globally. The episode touches on the FDA's rollout of AI tools to expedite drug approvals, highlighting the need for regulatory reform in the face of technological advancements. The hosts express optimism about the future of AI and robotics, particularly in healthcare and eldercare, as well as the potential for humanoid robots to revolutionize industries. Elon Musk's ventures, including Tesla and the Boring Company, are also examined. The hosts note the importance of Musk's ability to manage multiple companies and the potential for Tesla's stock to rebound as it pivots towards autonomous vehicles and robotics. Finally, the episode addresses demographic challenges, particularly declining birth rates in countries like South Korea and China, and the implications for global labor markets. The hosts conclude by emphasizing the transformative power of technology and the need for individuals and organizations to adapt quickly to these changes.

A bold mission to fix science from the inside out unfolds as NIH director Bhattacharya lays out a Silicon Valley–inspired portfolio. Six months in, he launches a $50 million autism data-science initiative, with 250 teams applying and 13 receiving grants to pursue data-driven answers for families. He cites the CDC’s estimate of autism at 1 in 31 and argues for therapies that actually work and clearer causes to guide prevention. One funded effort centers on folinic acid treatment delivering brain folate, improving outcomes for some children with deficient folate processing, including speech in a subset. Not all benefit, but wider access could help. A second thread urges caution with prenatal acetaminophen use, noting evidence of autism risk and signaling guideline changes. He also highlights a cross-agency push on pre-term birth to narrow the US–Europe gap in prenatal care. The dialogue then shifts to the replication crisis in science, born from volume and conservative peer review. Bhattacharya, a longtime grant-panelist, argues that ideas stall because reviewers cling to familiar methods and fear novelty. He describes NIH reforms modeled on venture capital: centralized grant reviews, empowering institute directors to curate portfolios, and rewarding success at the portfolio level rather than individual wins. He emphasizes funding early-career investigators to bring fresh ideas while evaluating mentorship of the next generation. The aim is a sustainable pipeline that balances risk and reward, mirrors scientific opportunity, and aligns with the institutes’ strategic plans. He calls for a broader, transparent conversation with Congress and the public about funding and progress toward healthier lives. He ties trust to gold-standard science—replication and open communication—and notes how HIV/AIDS-era public pressure redirected NIH priorities. The Silicon Valley analogy endures: a portfolio of bets, most fail, a few breakthroughs transform health. AI can accelerate discovery, streamline radiology, and optimize care, but should augment rather than replace scientists; safeguards must protect privacy while expanding open access and academic freedom. The long-term aim is to reduce chronic disease and improve life expectancy. He closes with Max Perutz’s persistence as a blueprint for patient science. He envisions an NIH that protects academic freedom, expands open publishing, and uses AI to augment, curating a diverse portfolio balanced by evidence and bold bets to lift health outcomes for all Americans.

Immigration policy, AI, and the future of work intersect as the economy weighs talent pipelines against cost. Hoffman notes Trump’s proposed $100,000 H-1B fee, and the idea he’s championed—make visas pricier but protect startups—could preserve innovation. Unlimited H1Bs with a high tax might deter outsourcing while keeping skilled workers here, with benefits through restaurants, housing, and services. The talk then turns to AI: a Stack Overflow survey shows 84% of developers use or will use AI, while 46% distrust the outputs. The question becomes how to improve trust without stifling progress and how to calibrate incentives for both large firms and startups. It then moves to medicine, where Hopkins data show a jump in predictive accuracy from 60% to 85% when AI is combined with context like age and procedure. The panel sees this as meaningful but notes ethics and transparency: AI outputs are probabilistic and require careful interpretation. Hoffman argues medicine has always operated on probabilities, and regulation should encourage experimentation while guarding against harm. Better tools can reveal patterns humans miss, and understanding why predictions arise can advance science even when the mechanism remains opaque. The discussion then touches work and a possible three-to-four day week: productivity gains suggest shorter weeks are possible, but global competition may slow adoption. The broader arc centers on trust in institutions and a philanthropy model. Lever for Change explains a five-finalist competition—American Journalism Project, Cal Matters, Recidiviz, Results for America, Transcend—that will share planning grants and aim for a final award, guided by experts, judges, and funders routing ideas to supporters. Hoffman warns that tearing down institutions is dangerous and renovation is essential. The finalists address local journalism, government transparency, recidivism data science, shared learning for local governments, and community-driven schooling, all with the goal of rebuilding trust. The talk highlights governance reform, measurement, and inclusive participation as key to resilience in a tech era.

This episode of Cold Fusion explores the dual nature of AI, distinguishing between consumer generative AI and traditional neural networks. A 2024 YouGov poll reveals that Americans feel caution, concern, skepticism, and curiosity towards AI, with younger individuals generally more positive. The episode highlights positive applications of AI in various fields, including disability support, medicine, and environmental restoration. In Tasmania, AI is used to map and restore the declining giant kelp population, which has dropped by 95% due to rising water temperatures. Google’s AI tools analyze satellite imagery to locate remaining kelp, aiding restoration efforts. AI-powered prosthetics are also discussed, showcasing advancements that allow users to perform everyday tasks. In healthcare, AI tools like Google's Med-LM enhance efficiency in patient care and drug discovery, significantly reducing costs and time. AI is also being utilized to develop next-generation batteries, with a notable study identifying materials that require 70% less lithium. The episode emphasizes that while AI has potential drawbacks, its positive impacts on society are increasingly evident.

A man faces a terminal illness with a radical idea: medicines we already have can cure what we lack. David Fajgenbaum’s journey begins with his mother’s brain cancer, a losing battle that fuels his vow to change medicine. As a medical student, he nearly dies from idiopathic multicentric Castleman disease, enduring dialysis, brief blindness, and last rites. He survives after intensive chemotherapy and vows to find treatments for others, while starting a grief support group named AMF, later Actively Moving Forward. Before long, chemotherapy isn’t enough. He discovers the drugs saving his life were not designed for Castleman’s, and asks: could there be an eighth drug repurposed from another disease? He researches globally, stores blood and tissue, and asks doctors to try drugs used elsewhere. In this crucible, he identifies a key insight: a drug to prevent organ rejection can suppress a harmful immune signal driving Castleman’s. He begins sirolimus and, after relapses, reaches durable remission, marrying Caitlyn in 2014 as his hair regrows. AI becomes his partner. He and Grant Mitchell co-found Every Cure to scan all 4,000 FDA-approved drugs against 18,000 diseases using a biomedical knowledge graph. The goal is to reveal which medicines might treat which conditions. In the first phase, 75 million matches are scored; the team of about 50 has reviewed the top 6,000, deep-dived into roughly 60–70, and advanced about 15 toward plans. Nine programs are active, including lidocaine for recurrence and a Jack inhibitor for Castleman’s. Nonprofit funding plus ARPA-H supports scale. The human side continues. They share successes: Michael with metastatic angiosarcoma responded to pembrolizumab; Kyla, a Castleman’s patient, improved after a JAK inhibitor; Joey, a child at CHOP, showed rapid lab improvements. Caitlyn’s unwavering support culminates in their wedding day. They discuss dissemination: UpToDate is imperfect, and knowledge must reach doctors worldwide, not just scholars. They envision a future where AI-guided matches are tested in labs and moved into trials, expanding access and reducing suffering for thousands. The mission: unlock hidden cures in existing drugs and spread them widely.

The episode surveys how artificial intelligence is reshaping medicine, from diagnostics to drug discovery and patient care. Dr. Lloyd Minor, dean of Stanford Medical School, frames AI as medicine’s most consequential moment, enabling models trained on vast datasets to complement human expertise, reduce errors, and expand access, particularly in under-resourced settings. The conversation traces the evolution from electronic prescribing and basic clinical decision support to modern large language models and transformer-based systems that can sift through billions of data points to identify patterns, predict disease, and tailor therapies. A key theme is that AI will not replace clinicians but redefine roles: radiologists and pathologists, for example, may work more efficiently with AI, while retaining critical judgment and patient interaction. The discussion emphasizes safety, transparency, and public engagement in deploying AI, arguing for governance that includes patient privacy and ongoing evaluation of model performance to avoid bias. The guest offers concrete examples of AI’s impact on healthcare delivery, such as computer-assisted skin cancer evaluation that can triage cases in rural areas, and AI-assisted imaging that highlights overlooked findings for radiologists. In pathology, AI can aggregate data across health systems to improve diagnostic accuracy for rare tumors, leveraging volumes of data that exceed what any individual expert could review. AI also enhances drug discovery by mapping protein structures from sequences and enabling the design of new therapeutics or refined clinical trials, ushering in a broader vision of Precision Health that seeks to anticipate and prevent disease rather than react after onset. Wearable devices and consumer health data are presented as catalysts for real-time monitoring, with Apple Heart Study highlighted as proof of feasibility for detecting atrial fibrillation, and glucose, blood pressure, and other metrics poised to become more routinized in daily life. The transcript delves into medical education’s transformation, predicting diminished emphasis on memorization and greater focus on data literacy, critical skepticism about AI outputs, and training that uses AI as a tool for inquiry. Virtual reality and simulation are described as supplements to cadaver work and surgical planning, while nutrition and behavioral science gain traction as essential components of a preventive paradigm. The guest also addresses ethical concerns—privacy, data bias, and preserving patient–provider relationships—calling for responsible regulation and public transparency. Finally, while acknowledging systemic healthcare challenges, the talk remains optimistic about incremental, practical changes that improve detection, prevention, and patient engagement in the near to mid-term future.

The episode features Jillian Michaels and Brigham Buhler discussing a healthcare system they view as corrupted by powerful entities in pharma and insurance. Buhler recounts his arc from a drug rep to founder of Ways to Well and Revive, detailing how Big Pharma and Big Insurance operate as a cartel that denies, delays, and obstructs patient care to protect profits. He argues that patients are frequently steered away from comprehensive, preventive health strategies toward expensive, disease-driven interventions, highlighting the tension between access to care and the realities of a business-first system. The conversation centers on how misaligned incentives drive up costs while undermining outcomes, from bloated drug prices to opaque rebate structures managed by pharmacy benefit managers (PBMs). They delve into compounding pharmacies as a double-edged sword: essential for affordable, personalized medications and often caricatured by critics, yet targeted by litigation from big manufacturers. Buhler explains the rigorous safety standards some compounding shops uphold, including sterile compounding and third-party validations, while noting the broader problem of 510(k) loopholes and insufficient human trials for many medical devices. The pair also scrutinize GLP-1s and the broader trend of overprescribing, arguing that root causes—nutrition, diet, lifestyle—are underexploited levers for health but underfunded by a system geared toward pharmacologic fixes and chronic revenue. They discuss the cost barriers to advanced diagnostics and preventive testing, pharmacogenetic testing, and the role of comprehensive panels in shaping personalized care. Buhler envisions a future where AI-driven monitoring, predictive testing, and cash-pay clinics like Ways to Well empower individuals to take sovereignty over their health, reduce dependence on insurers, and extend healthspan rather than merely chasing disease management. The dialogue also touches RFK, Casey Means, Callie, and a broader movement advocating diet, prevention, and autonomy, urging listeners to invest in proactive health strategies and to scrutinize the incentives shaping modern medicine. The episode closes with a practical note on affordability, stressing that deeper health insights need not be prohibitively expensive and that a comprehensive baseline can be attained for a few hundred dollars yearly. topics Big Pharma, Big Insurance, healthcare cartels, denials and delays, compounding pharmacies, 510k loopholes, FDA oversight, GLP-1s, preventive medicine, nutrition and lifestyle, predictive medicine, AI in healthcare, Ways to Well, Wastewell, pharmacogenetics, healthspan, RFK, Casey Means, Callie otherTopics Bayer and historical drug testing, opioid crisis, Sackler family history, insulin pricing and PBMs, shadow bans in media, the role of regulation in innovation, privacy concerns with AI health monitoring booksMentioned Bottle of Lies

In this conversation, Peter Diamandis and Balaji Srinivasan discuss various themes surrounding innovation, technology, and the future of society. Balaji emphasizes the importance of moral alignment among activists to create a market for transformative ideas, suggesting that clearing bureaucratic obstacles can enable significant advancements. They explore the potential of augmented reality (AR) glasses and the metaverse as convergence technologies that could reshape how we interact and communicate. Peter shares his morning routine, highlighting the importance of time management and prioritization for productivity. Balaji discusses the concept of "one meal a day" (OMAD) and its benefits, including increased energy and focus. They also touch on the challenges of social eating and how cultural norms can impact dietary choices. The conversation shifts to the regulatory landscape, particularly the FDA's role in hindering medical innovation. Balaji argues that the U.S. is experiencing a decline in longevity despite its wealth, attributing this to bureaucratic inefficiencies and a risk-averse culture. He suggests that it may be easier to start a new country than to reform the FDA, advocating for a "right to try" approach for patients seeking experimental treatments. They discuss the potential for AI and machine learning to revolutionize healthcare, including predictive technologies that could assess longevity based on facial recognition. Balaji proposes an X Prize for developing a longevity predictor app that could estimate life expectancy and suggest interventions. The dialogue also addresses the need for investigative journalism to expose regulatory abuses and the importance of moral arguments in driving innovation. Balaji believes that a coalition of like-minded individuals can unlock biomedical advancements and create a new political landscape focused on health and longevity. Finally, they contemplate the future of network states, with Balaji expressing optimism about the feasibility of establishing new countries that prioritize innovation and human flourishing. He envisions a coalition that can advocate for longevity and other critical issues, emphasizing the moral imperative to pursue these goals.